Compare Stocks

→ Just Released: Insider's Secret to Trading Options (From Schaeffer’s Research) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EQT EQT	$39.42 +3.8%	$36.19	$30.84 ▼ $45.23	$17.36B	1.12	6.55 million shs	11.73 million shs
SLS SELLAS Life Sciences Group	$1.54 -5.5%	$1.18	$0.50 ▼ $1.91	$86.66M	2.35	1.47 million shs	1.31 million shs

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EQT EQT	+3.79%	+9.41%	+13.24%	+9.33%	+24.31%
SLS SELLAS Life Sciences Group	-5.52%	+9.22%	+48.08%	+203.81%	+10.79%

$25,000 into $109,616 in two months? (Ad)

Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…

Go here to watch the most recent trading workshop video at no charge.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EQT EQT	4.3619 of 5 stars	3.3	2.0	2.5	0.0	2.5	1.7	3.1
SLS SELLAS Life Sciences Group	0.7314 of 5 stars	3.5	2.0	0.0	0.0	1.1	0.0	0.0

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EQT EQT	2.56	Moderate Buy	$44.06	11.78% Upside
SLS SELLAS Life Sciences Group	3.00	Buy	$3.00	94.81% Upside

Current Analyst Ratings

Latest MRCH, ICGT, EQT, and SLS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/24/2024	EQT EQT	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$46.00 ➝ $47.00
4/19/2024	EQT EQT	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$47.00 ➝ $41.00
4/19/2024	EQT EQT	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold	$43.00
4/17/2024	EQT EQT	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$37.00 ➝ $49.00
4/17/2024	EQT EQT	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$48.00 ➝ $37.00
4/16/2024	EQT EQT	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$39.00 ➝ $40.00
4/11/2024	EQT EQT	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sector Perform ➝ Sector Outperform	$40.00 ➝ $52.00
4/10/2024	EQT EQT	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Market Perform	$27.00 ➝ $34.00
4/5/2024	EQT EQT	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$37.00 ➝ $35.00
4/5/2024	EQT EQT	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$42.00 ➝ $43.00

(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EQT EQT	$6.91B	2.51	$6.81 per share	5.79	$35.93 per share	1.10
SLS SELLAS Life Sciences Group	$1M	86.66	N/A	N/A	($0.25) per share	-6.16

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EQT EQT	$1.74B	$4.25	9.28	9.95	N/A	25.12%	7.12%	4.03%	7/23/2024 (Estimated)
SLS SELLAS Life Sciences Group	-$37.34M	-$1.36	N/A	∞	N/A	N/A	-2,405.54%	-241.00%	5/9/2024 (Estimated)

Latest MRCH, ICGT, EQT, and SLS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
4/23/2024	Q1 2024	EQT EQT	$0.65	$0.82	+$0.17	$1.41	$1.58 billion	$1.30 billion
3/28/2024	Q4 2023	SLS SELLAS Life Sciences Group	N/A	-$0.25	-$0.25	-$0.25	N/A	N/A
2/13/2024	Q4 23	EQT EQT	$0.47	$0.48	+$0.01	-$0.17	$1.58 billion	$1.55 billion

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EQT EQT	$0.63	1.60%	+172.57%	14.82%	2 Years
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	N/A

Latest MRCH, ICGT, EQT, and SLS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/17/2024	EQT EQT	quarterly	$0.1575	1.75%	5/7/2024	5/8/2024	6/1/2024
2/8/2024	EQT EQT	quarterly	$0.1575	1.81%	2/16/2024	2/20/2024	3/1/2024

(Data available from 1/1/2013 forward)

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EQT EQT	0.37	0.99	0.99
SLS SELLAS Life Sciences Group	N/A	0.23	0.23

Ownership

Institutional Ownership

Company	Institutional Ownership
EQT EQT	90.81%
SLS SELLAS Life Sciences Group	17.38%

Insider Ownership

Company	Insider Ownership
EQT EQT	0.63%
SLS SELLAS Life Sciences Group	1.60%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
EQT EQT	881	440.43 million	437.65 million	Optionable
SLS SELLAS Life Sciences Group	17	56.27 million	55.37 million	Not Optionable

MRCH, ICGT, EQT, and SLS Headlines

Source	Headline
	Sellas Life Sciences Group: A Lottery Ticket With An Estimated 9x Payout seekingalpha.com - April 19 at 3:11 PM
	Seligman Launches a New Health Care Fund institutionalinvestor.com - March 28 at 7:32 PM
	SELLAS Life Sciences Group files for $200M mixed shelf msn.com - March 28 at 7:32 PM
	SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update globenewswire.com - March 28 at 4:05 PM
	Buy Rating for SELLAS Life Sciences Amid Positive AML Study Results and Strengthened Financials markets.businessinsider.com - March 27 at 10:54 PM
	SELLAS Phase 2a Study Of SLS009 In R/r AML Positive; Updates Phase 3 REGAL Study markets.businessinsider.com - March 26 at 10:33 AM
	SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study globenewswire.com - March 26 at 7:35 AM
	SELLAS Life Sciences Group Inc. wsj.com - March 21 at 3:15 PM
	SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules globenewswire.com - March 19 at 4:05 PM
	SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET globenewswire.com - March 19 at 8:47 AM
	Sellas Life Sciences Shares Drop 31% After Direct Offering Prices marketwatch.com - March 16 at 2:16 PM
	Geron, Graphite Bio, Immuneering among healthcare movers msn.com - March 15 at 10:20 AM
	SELLAS Life Sciences looks to raise $20M in a direct offering msn.com - March 15 at 10:20 AM
	Sellas Announces $20 Mln Registered Direct Offering, Concurrent Private Placement markets.businessinsider.com - March 15 at 10:20 AM
	SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules finance.yahoo.com - March 15 at 9:14 AM
	SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules globenewswire.com - March 15 at 9:00 AM
	Aadi Bioscience Q4 2023 Earnings Preview seekingalpha.com - March 12 at 12:49 PM
	Sellas Life Sciences Group Inc (SLS) investing.com - March 10 at 5:06 AM
	SELLAS Life Sciences Group, Inc.: SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships finanznachrichten.de - March 9 at 3:43 PM
	SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships globenewswire.com - March 8 at 8:00 AM
	SLS Mar 2024 4.000 put finance.yahoo.com - March 7 at 11:22 PM
	SELLAS Life Sciences Group, Inc. (SLS) finance.yahoo.com - March 1 at 3:52 PM
	SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference globenewswire.com - March 1 at 8:30 AM
	SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time globenewswire.com - February 29 at 8:00 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

EQT

NYSE:EQT

EQT Corporation operates as a natural gas production company in the United States. The company sells natural gas and natural gas liquids to marketers, utilities, and industrial customers through pipelines located in the Appalachian Basin. It also offers marketing services and contractual pipeline capacity management services. The company was formerly known as Equitable Resources Inc. and changed its name to EQT Corporation in February 2009. EQT Corporation was founded in 1878 and is headquartered in Pittsburgh, Pennsylvania.

SELLAS Life Sciences Group

NASDAQ:SLS

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. The company is headquartered in New York, New York.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial